Literature DB >> 3490935

Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome.

N Miyasaka, N Murota, K Yamaoka, K Sato, T Yamada, T Nishido, M Okuda.   

Abstract

We studied interleukin 2 (IL-2) production both in the peripheral blood and the lung in patients with Sjögren's syndrome (SS). IL-2 production of the peripheral blood mononuclear cells (PBMC) was significantly impaired in patients with SS (P less than 0.001). The patients with extraglandular disease and with associated connective tissue disease were more defective in IL-2 production. The defect could not be attributable to culture conditions. Both OKT4+ and OKT8+ T cells were deficient in producing IL-2. However, impaired IL-2 production could be partly restored by either (1) adding PMA to the PHA-stimulated culture, or (2) supplementing indomethacin (IM) from the initiation of the culture, or (3) depletion of adherent cells from PBMC. Furthermore, SS T cells were more sensitive to PGE1 than normal controls. In contrast, the response of PBMC to IL-2 was not disturbed in SS. IL-1 production of SS PBMC was not defective although there seemed to be suppressive factor(s) produced by SS adherent cells. In addition, IL-2 production of SS pulmonary lymphocytes was also decreased, suggesting that IL-2 producing cells might not be sequestrated in the lung. These data suggest that qualitative T cell defects and suppressor macrophages might be responsible for defective IL-2 production in SS and that IL-2 deficiency may contribute to the disordered immunoregulation in SS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490935      PMCID: PMC1542504     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Regulation of lymphocyte-activating factor (LAF) production and secretion in P388D1 cells: identification of high molecular weight precursors of LAF.

Authors:  S B Mizel; D L Rosenstreich
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

2.  Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70.

Authors:  J S Goodwin; R P Messner
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

3.  Preparation of lymphocyte-activating factor from continuous murine macrophage cell lines.

Authors:  L B Lachman; M P Hacker; G T Blyden; R E Handschumacher
Journal:  Cell Immunol       Date:  1977-12       Impact factor: 4.868

Review 4.  The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses.

Authors:  J J Farrar; W R Benjamin; M L Hilfiker; M Howard; W L Farrar; J Fuller-Farrar
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Lymphocyte adherence in multiple sclerosis. Role of monocytes and increased sensitivity of MS lymphocytes to prostaglandin E.

Authors:  P Dore-Duffy; R B Zurier
Journal:  Clin Immunol Immunopathol       Date:  1981-06

6.  Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

7.  Decreased autologous mixed lymphocyte reaction in Sjögren's syndrome.

Authors:  N Miyasaka; B Sauvezie; D A Pierce; T E Daniels; N Talal
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.

Authors:  Y Murakawa; S Takada; Y Ueda; N Suzuki; T Hoshino; T Sakane
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  Prostaglandin E inhibits the production of human interleukin 2.

Authors:  R S Rappaport; G R Dodge
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  5 in total

1.  Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture.

Authors:  M Goto; M Sasano; H Yamanaka; N Miyasaka; N Kamatani; K Inoue; K Nishioka; T Miyamoto
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

2.  Immunological and immunohistochemical analysis of rheumatoid nodules.

Authors:  N Miyasaka; K Sato; K Yamamoto; M Goto; K Nishioka
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

3.  Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.

Authors:  E Flescher; T L Bowlin; A Ballester; R Houk; N Talal
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

5.  Interleukin 2 (IL 2) inhibitor in rheumatoid synovial fluid: correlation with prognosis and soluble IL 2 receptor levels.

Authors:  P Miossec; M Elhamiani; B Chichehian; A D D'Angeac; J Sany; M Hirn
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.